Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Y-mAbs Therapeutics, Inc. (YMAB : NSDQ)

• Company Description    Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. Number of Employees: 148

• Price / Volume Information    Yesterday's Closing Price: $10.02 Daily Weekly Monthly 20 Day Moving Average: 644,749 shares Shares Outstanding: 43.71 (millions) Market Capitalization: $438.01 (millions) Beta: 1.48 52 Week High: $39.82 52 Week Low: $6.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.58% -3.80% 12 Week 25.09% 37.51% Year To Date -38.19% -25.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 230 Park Avenue Suite 3350 - NEW YORK,NY 10169 USA ph: 646-885-8505 fax: - info@ymabs.com http://www.ymabs.com

• General Corporate Information    Officers Claus Juan Moller San Pedro - Chief Executive Officer and Director Thomas Gad - Chairman of the Board of Directors;President Bo Kruse - Executive Vice President; Chief Financial Officer; Johan Wedell-Wedellsborg - Director Laura J. Hamill - Director Peer Information Y-mAbs Therapeutics, Inc. (CORR.) Y-mAbs Therapeutics, Inc. (RSPI) Y-mAbs Therapeutics, Inc. (CGXP) Y-mAbs Therapeutics, Inc. (BGEN) Y-mAbs Therapeutics, Inc. (GTBP) Y-mAbs Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 984241109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 43.71 Most Recent Split Date: (:1) Beta: 1.48 Market Capitalization: $438.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.78 Price/Cash Flow: - Price / Sales: 10.95 EPS Growth vs. Year Ago Period: -185.33% vs. Previous Quarter: 24.71% Sales Growth vs. Year Ago Period: 94.80% vs. Previous Quarter: 9.25% ROE 03/31/22 - -59.67 12/31/21 - -25.20 09/30/21 - -19.08 ROA 03/31/22 - -51.70 12/31/21 - -22.40 09/30/21 - -16.91 Current Ratio 03/31/22 - 6.12 12/31/21 - 7.26 09/30/21 - 9.09 Quick Ratio 03/31/22 - 5.93 12/31/21 - 7.06 09/30/21 - 8.90 Operating Margin 03/31/22 - -291.89 12/31/21 - -158.40 09/30/21 - -83.21 Net Margin 03/31/22 - -291.89 12/31/21 - -158.40 09/30/21 - -83.21 Pre-Tax Margin 03/31/22 - -291.89 12/31/21 - -158.40 09/30/21 - -83.21 Book Value 03/31/22 - 3.60 12/31/21 - 4.13 09/30/21 - 4.84 Inventory Turnover 03/31/22 - 0.82 12/31/21 - 0.61 09/30/21 - 0.35 Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©